The FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the PIK3CA mutation in this disease.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh